Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01170338

Enrollment

100

Registered

2010-07-27

Start date

2008-01-31

Completion date

Unknown

Last updated

2010-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Smoking

Keywords

smoking, tobacco abuse

Brief summary

Assess the role of a nicotine antagonist in helping patients presenting to hospital with acute coronary syndrome to stop smoking.

Interventions

DRUGVarenicline 100 mg by mouth twice daily

this is an active drug to help smoking cessation

DRUGcontrol

this is the placebo that will help us maintain a blinded study

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* active smokers presenting to hospital with an acute coronary syndrome

Exclusion criteria

* patients with an acute coronary syndrome who are not active smokers

Design outcomes

Primary

Measure	Time frame
nicotine levels	1 month

Secondary

Measure	Time frame
recurrent myocardial ischemia	1 month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026